SB1344 updates Arizona’s newborn screening law to require the Department of Health Services to maintain a newborn screening program for congenital disorders and hearing loss, with testing and reporting procedures set by rule. The bill keeps the existing requirement that newborn screening include disorders on the federal Recommended Uniform Screening Panel, and it preserves the general rule that newly added federal conditions must be added to Arizona’s panel within two years. It also requires the program to maintain a central database, provide follow-up services for families when screening suggests a possible disorder or hearing loss, and operate an education program for the public, medical community, parents, and professional groups.
The bill also formalizes program administration and financing. It authorizes the department to establish a fee to operate the program and contract for testing, requires any fee change to be reviewed by the Joint Legislative Budget Committee, and directs insurers and AHCCCS to update hospital rates to reflect any fee increase within 60 days. The bill defines “newborn” and “infant” for purposes of the section and clarifies that the state laboratory is the default testing facility, while allowing other laboratories for certain conditions or tests under specified privacy and sample-destruction requirements.
Impact
SB1344 amends A.R.S. § 36-694, the statute governing Arizona’s newborn screening program, by refining how congenital disorder and hearing-loss screening is administered, reported, and funded. It affects the Department of Health Services, hospitals, physicians, laboratories, health insurers regulated under Title 20, and AHCCCS contractors by tying reimbursement and hospital rates to program fee changes. It also reinforces confidentiality protections for screening data and preserves the state’s authority to expand the screening panel in line with federal recommendations, subject to a limited exception when no FDA-approved commercial test exists and a laboratory-developed test would require FDA review.
Sentiment
The bill appears to have been broadly supported and noncontroversial. It passed the Senate Health and Human Services Committee 7-0, the House Health & Human Services Committee 12-0, and both chambers’ floor votes unanimously or near-unanimously, including 29-0 in the Senate and 55-0 in the House. The available record suggests a consensus that the measure is a routine public health update aimed at improving newborn screening operations and follow-up care.
Contention
There is little evidence of substantive opposition in the available record. The only potentially notable policy issue is the bill’s fee authority and the requirement that insurers and AHCCCS adjust rates when the department changes the newborn screening fee, which could affect payers and hospitals. Another technical point is the exception to the two-year deadline for adding new disorders to the screening panel when no commercially available FDA-approved test exists and a laboratory-developed test would need FDA review. However, no recorded committee debate or votes indicate these issues generated significant contention.